A multivariate analysis of CAMPAS-PX2 can increase its diagnostic accuracy in differential diagnosis of pancreatic cancer from benign pancreatic or extrapancreatic disease, when compared with CA19-9 alone.
However, the improvement in diagnostic accuracy is still not satisfactory in spite of an elaborate combination of serum markers in diagnosis for pancreatic cancer.
Optimal combination of a sensitive serum marker and another diagnostic modality, such as ultrasonography, can be a practical way to improve important diagnostic and cost-effectiveness in diagnosis for pancreatic cancer.
No specific biological test has yet been developed for diagnosis of pancreatic cancer, although increasing numbers of tumor markers become available.
For improvement in the diagnostic and cost effectiveness, it is important to select optimal combination of several serum markers relatively independent of each other.
A new model of discriminant function, computer-aided multivariate and pattern analysis system for pancreatic cancer examination 2 (CAMPAS-PX2), was developed based on the data of the 23 serum tumor markers from the first prospective trial (1) to differentiate between pancreatic cancer and benign pancreatobiliary disease by logistic regression analysis using a stepwise selection method. (...)
Mots-clés Pascal : Tumeur maligne, Pancréas, Diagnostic différentiel, Tumeur bénigne, Marqueur biologique, Etude multicentrique, Sérologie, Analyse statistique, Analyse multivariable, Prévalence, Résultat, Analyse coût efficacité, Homme, Japon, Asie, Appareil digestif pathologie, Pancréas pathologie, Biologie moléculaire, Statistique
Mots-clés Pascal anglais : Malignant tumor, Pancreas, Differential diagnostic, Benign neoplasm, Biological marker, Multicenter study, Serology, Statistical analysis, Multivariate analysis, Prevalence, Result, Cost efficiency analysis, Human, Japan, Asia, Digestive diseases, Pancreatic disease, Molecular biology, Statistics
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0201970
Code Inist : 002B13C01. Création : 16/11/1999.